Definitive Contract W911SR25CA011
- Not listed
- This is a $149,748.85 firm fixed-price purchase order awarded by the U.S. Army's Research, Development, and Engineering Command (RDECOM) to Hygratek LLC, a small business located in Ann Arbor, Michigan. The contract is for the Small Business Innovation Research (SBIR) program Phase I effort to develop durable aerosol and liquid repellent coatings. As a total small business set-aside contract, this award does not involve any subcontractors. The contract has an ultimate completion date of...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the U.S. Army Research, Development and Engineering Command (RDECOM) to New England Research & Development, LLC, a for-profit limited liability company. The objective of the $99,519.72 firm-fixed-price contract is to develop a coarse-grained discrete-element method for modeling multi-fluid systems, overcoming limitations of traditional Eulerian mixture theory approaches. The contract was awarded on February 7,...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the U.S. Army Research, Development and Engineering Command (RDECOM) to TDA Research, Inc., a small business based in Golden, Colorado. The contract has a ceiling value of $745,710.72 and is a definitive, firm-fixed-price contract. The award is associated with the SBIR program, which funds the research and development of innovative technologies by small businesses. The contract supports continued Phase II work,...
- The Department of the Army Medical Command awarded a Firm Fixed Price Definitive Contract to TDA Research, Inc., a for-profit subchapter S corporation located in Wheat Ridge, Colorado. The $149,988.69 contract was awarded under the SBIR Program Phase I to develop an Intelligent Thermal Desorption Tube Sequential Sampler. This award is set aside for small businesses. TDA Research provides research, engineering, and technical services to U.S. federal government agencies, and has been awarded...
- This is a firm-fixed-price SBIR Phase I contract awarded by the Defense Health Agency (DHA) to Advanced Cooling Technologies, Inc. (ACT), a small business based in Neffsville, Pennsylvania. The contract, valued at $249,998.51, is for the development of a psoralen-UV-A irradiation-based high-throughput pathogen inactivation device. As an SBIR Phase I award, this contract is set aside for small businesses to conduct research and explore the feasibility of innovative technologies that can address a...
- This is a $249,988.57 firm fixed-price Phase I SBIR contract awarded by the Defense Health Agency (DHA) to TDA Research, Inc., a small business based in Colorado. The contract is for the development of a psoralen-UV-A inactivation-based high-throughput pathogen inactivation device. This SBIR contract supports research and development of an innovative medical device technology. TDA Research is an experienced government contractor, holding multiple SBIR and STTR awards as well as other federal...
- This is a $149,948.97 Small Business Innovation Research (SBIR) Phase I contract awarded by the U.S. Army Research, Development and Engineering Command (RDECOM) to Altex Technologies Corporation, a small business. The contract supports the development of Altex's Portable Bi-functional Desalination (PBD) technology, which combines photocatalysis and ion-exchange to purify seawater and brackish water for soldiers. Texas A&M Engineering Experiment Station (Tees) is a subcontractor on the...
- The U.S. Army Research Development and Engineering Command has awarded Rivis, Inc., a small business, a $149,999.15 firm fixed-price contract under the Small Business Innovation Research (SBIR) program. The contract is for research and development efforts to create an atmospheric pressure plasma reactor capable of extended solids production, which may have applications related to the coronavirus pandemic. Rivis, Inc. is a for-profit small business spin-off of the non-profit International...
- This is a $149,873 firm-fixed-price SBIR Phase I contract awarded by the Medical Command of the U.S. Department of Defense to TDA Research, Inc., a small business based in Golden, Colorado. The contract is for the project "Novel Rewarming Technique for Cryopreserved Tissue" under the SBIR 15.1 H151-014-0172 solicitation. TDA Research has expertise in materials science, medical devices, and other technology areas relevant to this SBIR research. The contract has a total small business...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Health Agency (DHA) to TDA Research, Inc., a for-profit subchapter S corporation located in Wheat Ridge, Colorado. The $249,999.88 firm fixed-price purchase order is for medical research and development related to a "NANO-SYNTHETIC MATERIALS SMART SYSTEM ENABLING SENSOR DISCOVERY AND FABRICATION." TDA Research specializes in materials science, chemical and environmental technologies, medical...
The U.S. Army Research, Development and Engineering Command (RDECOM) awarded a $209.6K Small Business Innovation Research (SBIR) Phase I contract to Inaedis, Inc., a Princeton, New Jersey-based biopharmaceutical technology company, on July 29, 2025. The effort focuses on demonstrating the feasibility and efficacy of Rapid Room-Temperature Aerosol Dehydration (RTAD) technology for producing shelf-stable, bioactive powders with controllable nanoparticle morphology. This total small business set-aside contract is structured as a definitive, firm fixed-price engagement with a completion date of January 28, 2026, and work to be performed in Princeton, New Jersey. Inaedis, Inc. has been developing this RTAD platform technology through prior NSF and National Center for Advancing Translational Sciences grants to address critical challenges in the thermal stabilization of temperature-sensitive biologics, vaccines, and pharmaceutical compounds. The technology enables continuous dehydration of liquid pharmaceutical formulations at room temperature, preserving the integrity of sensitive biological molecules including proteins, enzymes, and viral vectors. This Phase I effort will validate the technical approach and establish proof-of-concept for a scalable system with potential applications across pulmonary, nasal, and transdermal drug delivery, while supporting broader goals of improving vaccine stability, reducing cold chain logistics requirements, and minimizing pharmaceutical wastage.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $209.6k | 7/29/25 |